BioSpace

Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial

Kodiak Sciences will head to regulators with one of the candidates, an anti-VEGF antibody called zenkuda, after the late-stage results.

By BioSpace

1 min read
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights